Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Simcere’s Q2 Revenue Below Expectations

publication date: Aug 5, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group reported significantly improved Q2 financials today, but the results came in below analysts' estimates and the company reduced its guidance for full-year 2008. The disappointments caused a 4% selloff in the company’s stock price. Simcere blamed the shortfall on two problems: Endu revenue growth was lower than expected because the company restructured its Endu sales force. Also, Simcere is giving away Endu to accelerate participation in a Phase IV clinical trial of the drug, resulting in lower-than-projected sales. More details...

Stock Symbol: (NYSE: SCR)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners